

Special Issue

Treatment of Bone Metastases including Metastatic Spinal Cord Compression

Message from the Guest Editors

Bone metastases are quite common in cancer patients. Five to 10% of patients even develop metastatic spinal cord compression (MSCC) during the course of their disease. Due to the improvement in the treatment of primary tumors, more patients live longer and are at a higher risk of developing bone metastases and MSCC. Therefore, these patients will require increasing attention. Treatment of bone metastases provides a multidisciplinary challenge. This is particularly true for MSCC which is considered an oncologic emergency. Moreover, it is important to further improve the outcomes of the patients with modern personalized treatment approaches based on available research data. Therefore, we would like to invite you to submit original and review articles that contribute to the improvement of the treatment of bone metastases and MSCC. There is a particular interest in articles reporting on new approaches and techniques in the involved disciplines and in articles contributing to the personalization of the treatment.

Guest Editors

Prof. Dr. Dirk Rades

Department of Radiation Oncology, University of Lübeck, Ratzeburger Alle 160, 23562 Lübeck, Germany

Prof. Dr. Steven E. Schild

Department of Radiation Oncology, Mayo Clinic Scottsdale, 13400 E. Shea Boulevard, Scottsdale, AZ 85259, USA

Deadline for manuscript submissions

closed (31 August 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/97862

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)